The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 63 percent year over year.
Test volume for its Cologuard test was up 63 percent year over year, while test volume for Genomic Health's Oncotype DX jumped 14 percent.
Gainers in the index outpaced the decliners 19 to nine, and the index outpaced the Dow Jones Industrial Average and Nasdaq Biotechnology Index but lagged the Nasdaq.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
While higher recurrence scores have been associated with increased mortality in women, the pattern of the association differed among male patients.
News items for the week of Nov. 4, 2019.
The company reported increase US and international revenues and test volumes, driven by increased adoption and expanding public and private payor coverage.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.
After the merger closes, the combined company will be split into four units focused on Cologuard, Oncotype Dx, international business, and pipeline efforts.